Combination chemotherapy regimen

This page covers all Combination chemotherapy regimen drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition), Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin), Thymidylate synthase (5-FU); DNA (oxaliplatin).

Targets

DNA (multiple mechanisms: alkylation, cross-linking, topoisomerase II inhibition) · Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin) · Thymidylate synthase (5-FU); DNA (oxaliplatin) · Thymidylate synthase (5-FU), DNA (oxaliplatin) · DNA synthesis machinery; Topoisomerase II · DNA (topoisomerase I for irinotecan; DNA cross-linking for oxaliplatin; thymidylate synthase for 5-FU) · DNA (anthracycline); glucocorticoid receptor (dexamethasone) · Multiple: thymidylate synthase, topoisomerase I, DNA (cross-linking) · Thymidylate synthase (capecitabine); DNA (oxaliplatin)

Marketed (8)

• Dexamethasona, Idarubicine, ARA-C, Methotrexate · PETHEMA Foundation · Oncology
  This is a combination chemotherapy regimen that uses a corticosteroid, an anthracycline topoisomerase II inhibitor, a nucleoside antimetabolite, and a folate antagonist to kill rapidly dividing leukemic cells through multiple mechanisms.
• CVP · SCRI Development Innovations, LLC · Oncology
  CVP is a chemotherapy regimen combining cyclophosphamide, vincristine, and prednisone to suppress cancer cell growth through multiple cytotoxic and immunosuppressive mechanisms.
• SOX Chemotherapy · The First Affiliated Hospital with Nanjing Medical University · Oncology
  SOX is a combination chemotherapy regimen that uses S-1 (an oral fluoropyrimidine) and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
• Carboplatin, Etoposide, Ifosfamide · University Hospital Muenster · Oncology
  This combination of three chemotherapy agents works by damaging DNA and preventing cancer cell division through different mechanisms: carboplatin and ifosfamide cross-link DNA strands, while etoposide inhibits topoisomerase II.
• chemotherapy of mFOLFOX6 or FOLFIRI · Xu jianmin · Oncology
  mFOLFOX6 and FOLFIRI are combination chemotherapy regimens that inhibit DNA synthesis and cell division through multiple mechanisms targeting rapidly dividing cancer cells.
• Consolidation Chemotherapy · National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos · Oncology
  Consolidation chemotherapy uses a combination of cytotoxic agents to eliminate residual cancer cells remaining after initial treatment and reduce the risk of disease relapse.
• CEV chemotherapy · Sun Yat-sen University · Oncology
  CEV is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit cancer cell division and induce apoptosis.
• FEC · Hoffmann-La Roche · Oncology
  FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.

Phase 3 pipeline (41)

• CMF Chemotherapy · Universitätsklinikum Hamburg-Eppendorf · Oncology
  CMF is a combination chemotherapy regimen that uses three cytotoxic agents to inhibit cancer cell division and induce apoptosis.
• mFOLFOX 6 · Chungnam National University Hospital · Oncology
  mFOLFOX6 is a chemotherapy regimen that combines 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
• chemotherapy (CHOP) · Sun Yat-sen University · Oncology
  CHOP is a combination chemotherapy regimen that uses four cytotoxic agents to kill rapidly dividing cancer cells through multiple mechanisms of DNA damage and cell cycle disruption.
• FOLFOX chemotherapy regimen · Sixth Affiliated Hospital, Sun Yat-sen University · Oncology
  FOLFOX is a combination chemotherapy regimen that kills cancer cells by damaging DNA and preventing cell division through multiple mechanisms of action.
• Ara-C, Mitoxantrone, Daunorubicin, Thioguanin · Prof. Dr. Wolfgang Hiddemann · Oncology
  This is a combination chemotherapy regimen that includes cytarabine (Ara-C), mitoxantrone, daunorubicin, and thioguanine, which work together to inhibit DNA synthesis and induce apoptosis in leukemic cells.
• Epirubicin, cyclophosphamide and docetaxel · Danish Breast Cancer Cooperative Group · Oncology
  This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division, used in breast cancer treatment.
• Chemotherapy FOLFIRINOX, 6 cycles · University Hospital, Bordeaux · Oncology
  FOLFIRINOX is a combination chemotherapy regimen that damages cancer cell DNA through multiple mechanisms, preventing replication and inducing cell death.
• HyperCVAD · Amgen · Oncology
  HyperCVAD is a chemotherapy regimen that combines multiple cytotoxic agents to kill rapidly dividing cancer cells through DNA damage and cell cycle disruption.
• mFOLFIRINOX regimen · Revolution Medicines, Inc. · Oncology
  mFOLFIRINOX is a chemotherapy regimen combining 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
• FEC-DocGemzar adjuvant chemotherapy · Ludwig-Maximilians - University of Munich · Oncology
  FEC-DocGemzar is a combination chemotherapy regimen that uses multiple cytotoxic agents to kill rapidly dividing cancer cells in the adjuvant (post-surgical) setting.
• Neoadjuvant FOLFOX · Kyungpook National University Hospital · Oncology
  FOLFOX is a combination chemotherapy regimen that damages cancer cell DNA through multiple mechanisms to inhibit tumor growth and is used in the neoadjuvant setting to shrink tumors before surgery.
• Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase · Children's Cancer Group, China · Oncology
  This combination regimen uses a corticosteroid, cytotoxic chemotherapy agents, and an amino acid-depleting enzyme to induce apoptosis and inhibit protein synthesis in leukemic cells.
• FOLFOX 2d · Sun Yat-sen University · Oncology
  FOLFOX 2d is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin administered on a modified 2-day schedule to inhibit DNA synthesis and induce apoptosis in cancer cells.
• FOLFOX 1d · Sun Yat-sen University · Oncology
  FOLFOX 1d is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
• Docetaxel, nedaplatin, fluorouracil · Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Oncology
  This combination regimen uses a microtubule-stabilizing taxane, a platinum-based DNA crosslinker, and an antimetabolite to inhibit cancer cell division and induce apoptosis through multiple mechanisms.
• mFOLFIRINOX-FOLFIRI intensified chemotherapy · Seoul National University Hospital · Oncology
  mFOLFIRINOX-FOLFIRI is an intensified chemotherapy regimen combining fluorouracil, leucovorin, irinotecan, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
• FLOT chemotherapy · AstraZeneca · Oncology
  FLOT is a combination chemotherapy regimen that uses four cytotoxic agents to inhibit cancer cell division and induce apoptosis.
• Dose -mFOLFIRINOX · Pancreatic Cancer Action Network · Oncology
  mFOLFIRINOX is a combination chemotherapy regimen that uses multiple cytotoxic agents to damage cancer cell DNA and inhibit cell division.
• FOLFOX or · Alliance for Clinical Trials in Oncology · Oncology
  FOLFOX is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and cross-link DNA in cancer cells.
• FOLFOXIRI chemotherapy · Sun Yat-sen University · Oncology
  FOLFOXIRI is a combination chemotherapy regimen that uses three cytotoxic agents to inhibit DNA synthesis and cell division in cancer cells.
• FOLFOXIRI · Centre Hospitalier Universitaire de Besancon · Oncology
  FOLFOXIRI is a combination chemotherapy regimen that simultaneously inhibits DNA synthesis and repair through three complementary cytotoxic agents.
• ABVD q4 weeks · European Organisation for Research and Treatment of Cancer - EORTC · Oncology
  ABVD is a combination chemotherapy regimen that uses four cytotoxic agents to kill rapidly dividing cancer cells through multiple mechanisms including DNA alkylation, topoisomerase inhibition, and microtubule disruption.
• FLAG-IDA · Sunshine Lake Pharma Co., Ltd. · Oncology
  FLAG-IDA is a combination chemotherapy regimen that inhibits DNA synthesis and promotes apoptosis in rapidly dividing cells.
• FOLFRINOX · Zhejiang Cancer Hospital · Oncology
  FOLFRINOX is a combination chemotherapy regimen that uses multiple cytotoxic agents to inhibit DNA synthesis and cell division in cancer cells.
• FOLFIRINOX or gemcitabine-nab-paclitaxel · Sahlgrenska University Hospital · Oncology
  FOLFIRINOX and gemcitabine-nab-paclitaxel are combination chemotherapy regimens that kill rapidly dividing cancer cells through multiple mechanisms of DNA damage and microtubule disruption.
• Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine · National Cancer Center, Korea · Oncology
  This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and disrupt cell division through different mechanisms.
• Arm B: FOLFIRI or FOLFOX · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · Oncology
  FOLFIRI and FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluorouracil-based cytotoxic activity, with irinotecan targeting topoisomerase I or oxaliplatin targeting DNA cross-linking.
• FEC Chemotherapy · Hoffmann-La Roche · Oncology
  FEC is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.
• FOLFOX chemotherapy regimens · Sixth Affiliated Hospital, Sun Yat-sen University · Oncology
  FOLFOX is a combination chemotherapy regimen that uses 5-fluorouracil and leucovorin to inhibit thymidylate synthase and DNA synthesis, combined with oxaliplatin to create DNA crosslinks and prevent replication.
• FEC→T · Karolinska University Hospital · Oncology
  FEC→T is a sequential chemotherapy regimen combining fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel to kill rapidly dividing cancer cells.
• induction chemotherapy (mDCF) · Federation Francophone de Cancerologie Digestive · Oncology
  mDCF is a combination chemotherapy regimen that uses docetaxel, cisplatin, and fluorouracil to inhibit cancer cell division and induce apoptosis in gastric and esophageal cancers.
• Anthracycline/dexamethasone-based induction chemotherapy · WiSP Wissenschaftlicher Service Pharma GmbH · Oncology
  Anthracycline chemotherapy intercalates into DNA to prevent replication, while dexamethasone suppresses immune-mediated inflammation and enhances chemotherapy efficacy.
• GTP regimen · Beijing Friendship Hospital · Oncology
  GTP is a chemotherapy regimen combining gemcitabine, docetaxel, and cisplatin to inhibit cancer cell proliferation through multiple mechanisms.
• Neoadjuvant chemotherapy Folfirinox, 4 cycles · University Hospital, Bordeaux · Oncology
  FOLFIRINOX is a combination chemotherapy regimen that simultaneously attacks cancer cells through multiple mechanisms: fluorouracil and leucovorin inhibit thymidylate synthase to disrupt DNA synthesis, while irinotecan inhibits topoisomerase I to prevent DNA unwinding.
• IAC regimen · The First Affiliated Hospital of Soochow University · Oncology
  IAC regimen is a chemotherapy combination that uses ifosfamide, doxorubicin, and cisplatin to damage cancer cell DNA and inhibit tumor growth.
• FOFLOX4 · Guangdong Provincial People's Hospital · Oncology
  FOFLOX4 is a chemotherapy regimen combining fluorouracil, folinic acid (leucovorin), and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
• CapeOX（Capecitabine+Oxaliplatin） · Peking University Cancer Hospital & Institute · Oncology
  CapeOX combines capecitabine, a fluoropyrimidine prodrug that inhibits thymidylate synthase, with oxaliplatin, a platinum agent that forms DNA crosslinks, to provide synergistic cytotoxic activity against cancer cells.
• B arm (DAC) · Polish Adult Leukemia Group · Oncology
  DAC (daunorubicin, cytarabine, and cladribine) is a combination chemotherapy regimen that damages leukemic cell DNA and inhibits nucleotide synthesis to induce apoptosis.
• Prednisone+Cytarabine+vincristine+Mercaptopurine · Shanghai Children's Medical Center · Oncology
  This combination chemotherapy regimen suppresses leukemic cell proliferation through multiple mechanisms: corticosteroid immunosuppression, cytarabine-induced DNA damage, vincristine-mediated microtubule disruption, and mercaptopurine purine antagonism.
• cisplatin, mitomycin-C, doxifluridine · Asan Medical Center · Oncology
  This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.